Sai Life Sciences anticipates growth opportunities as global pharmaceutical supply chains shift, particularly following the US Department of Defense’s recent actions against Chinese biotech companies. The company’s CFO, Siva Chittor, noted that this trend may lead to accelerated outsourcing activities for Indian contract development and manufacturing organizations, with projected growth of 15-20% over the next few years. To capitalize on this potential, Sai Life Sciences has significantly increased its capital expenditure, from ₹250 crore two years ago to an expected ₹1,100-1,300 crore this year. The firm currently collaborates with 19 of the world’s top 25 pharmaceutical companies and sees emerging opportunities in the GLP-1 drug market. Despite challenges, the industry appears well-positioned to meet rising demand.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.cnbctv18.com/business/companies/sai-life-sciences-sees-strong-growth-runway-as-global-pharma-shifts-sourcing-beyond-china-19922103.htm
